The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial.
 
Harry Yoon
Consulting or Advisory Role - Amgen (Inst); Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; AstraZeneca; AstraZeneca (Inst); beigene; BeiGene (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology; Merck (Inst); Merck (Inst); Novartis (Inst); Zymeworks (Inst)
Research Funding - BeiGene (Inst); Bristol Myers Squibb Foundation (Inst); CARsgen Therapeutics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - beigene
 
Jianming Xu
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Yueyin Pan
No Relationships to Disclose
 
Sook Ryun Park
Honoraria - BMS Korea; MSD
Consulting or Advisory Role - BeiGene; Pfizer Pharmaceuticals Korea Ltd.
Research Funding - ImmuneOncia (Inst); Incyte (Inst); Ono Pharmaceutical
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; GlaxoSmithKline; Hookipa Biotech; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; TERUMO
 
Paula Jimenez-Fonseca
Speakers' Bureau - BMS GmbH & Co. KG; Lilly
Other Relationship - IPSEN
 
Frederick Barnes
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Tianmo Sun
Employment - BeiGene Beijing
Stock and Other Ownership Interests - BeiGene Beijing
 
Gisoo Barnes
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Timothy Victor
Employment - BeiGene
Consulting or Advisory Role - BeiGene